Companies
Lanzhou Biological
a subsidiary of China National Biotec Group (国药集团中国生物), the 30+ year national BoNT incumbent with 5,000+ medical institutions nationwide; 2025-2026 first-in-China indication expansions — primary axillary hyperhidrosis (NMPA approval November 25, 2025) and benign masseter hypertrophy (NMPA approval April 27, 2026,…
- Country
- China
First-in-China axillary hyperhidrosis (Nov 2025) + benign masseter hypertrophy (Apr 2026) NMPA approvals
cn
Coverage
| CN | EU | US | |
|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Total assets reached $3.6 billion as of 2018 | dcvmn.org · ivi.int |
| Capacity | Annual human vaccine capacity up to 700 million doses; plasma collection capability of 1,400-1,500 tons annually | dcvmn.org · ivi.int |
| Certification | Product sold to 30+ countries; first Chinese company pre-qualified by the WHO for botulinum toxin | dcvmn.org · phirda.com |
| Regulatory approval | Botulinum toxin type A (Hengli) approved for various indications since 1997, with new indications (primary axillary hyperhidrosis, masticatory muscle hypertrophy) dated 2025-2026 | dcvmn.org · synapse.patsnap.com · synapse.zhihuiya.com |
| Production site | 7 human vaccine manufacture sites, 2 animal vaccine manufacture sites, and 85 plasma collection stations nationwide | dcvmn.org · ivi.int |
| Headcount | Over 10,000 employees | dcvmn.org · ivi.int |
| Revenue | Total revenue reached $1.6 billion as of 2018 | dcvmn.org · ivi.int |
Independent sources: dcvmn.org · ivi.int · phirda.com · synapse.patsnap.com · synapse.zhihuiya.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Recombinant botulinum toxin (biosynthetic Botox) | specialty-fine-chem | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.